Table 5:

Patient factors associated with erlotinib treatment (multivariate analysis) – Patients who had a genetic test

	Model 1 – Without clinical variables		Model 2 – With clinical variables included
	OR (CI)	P-value	OR (CI)	P-value
SES Variables
Low income	0.31 (0.14, 0.72)	0.0064 *	0.32 (0.13, 0.79)	0.0131 *
High-poverty location	1.16 (0.61, 2.19)	0.6555	1.12 (0.58, 2.17)	0.7304
Demographic and Clinical Characteristics
Female	0.76 (0.42, 1.38)	0.3696	0.68 (0.36, 1.3)	0.2422
Black (vs. white)	1.72 (0.13, 23.64)	0.684	2.14 (0.14, 32.75)	0.5843
Asian (vs. white)	2.64 (0.27, 25.97)	0.4048	2.64 (0.26, 26.73)	0.4108
Hispanic (vs. white)	0.06 (0, 7.91)	0.2529	0.03 (0, 3.77)	0.1547
Other/unknown (vs. white)	4.04 (0.1, 156.89)	0.454	6.45 (0.16, 260.1)	0.3229
Urban location	2.13 (0.49, 9.24)	0.3115	2.16 (0.48, 9.71)	0.3159
Diagnosis year	0.93 (0.55, 1.56)	0.7763	0.87 (0.5, 1.51)	0.6181
Adenocarcinoma	-	-	1.26 (0.59, 2.66)	0.5506
Under 75 at diagnosis	-	-	1.13 (0.6, 2.12)	0.7003
Charlson index 3+ (vs. 0)	-	-	0.78 (0.16, 3.93)	0.7659
Charlson index 2 (vs. 0)	-	-	3.40 (0.83, 13.89)	0.0879
Charlson index 1 (vs. 0)	-	-	0.49 (0.15, 1.59)	0.2347
Diagnosis Year Interaction Variables
Low income	1.26 (1.03, 1.53)	0.0248 *	1.26 (1.02, 1.56)	0.034 *
High-poverty location	0.98 (0.83, 1.14)	0.771	0.99 (0.84, 1.16)	0.8966
Female	1.14 (0.98, 1.32)	0.0816	1.16 (0.99, 1.35)	0.0745
Black (vs. white)	0.72 (0.37, 1.4)	0.3303	0.72 (0.36, 1.43)	0.3462
Asian (vs. white)	0.88 (0.52, 1.51)	0.6526	0.87 (0.51, 1.51)	0.6246
Hispanic (vs. white)	2.15 (0.65, 7.07)	0.2074	2.42 (0.75, 7.78)	0.1385
Other/unknown (vs. white)	0.85 (0.36, 1.99)	0.7086	0.76 (0.32, 1.79)	0.5247
Urban location	0.90 (0.64, 1.27)	0.552	0.89 (0.63, 1.27)	0.5349
Adenocarcinoma	-	-	0.97 (0.8, 1.17)	0.753
Under 75 at diagnosis	-	-	0.93 (0.8, 1.09)	0.3778
Charlson index 3+ (vs. 0)	-	-	0.96 (0.65, 1.41)	0.8201
Charlson index 2 (vs. 0)	-	-	0.74 (0.52, 1.06)	0.0966
Charlson index 1 (vs. 0)	-	-	1.23 (0.93, 1.64)	0.1532

^*= Significant at the 0.05 level